The top researcher, Brian Kaspar, PhD, was let go from the company along with his brother Allan Kaspar, PhD, in May 2019. The brothers were both leading scientists at AveXis, the gene therapy unit of Novartis wrapped in a scandal over manipulated data in the Zolgensma application.
The drugmaker came under fire for its decision to delay informing the FDA about the erroneous data in its Zolgensma application until after it secured approval for the gene therapy that treats spinal muscular atrophy.
Dr. Brian Kaspar is defending his leadership and the approved gene therapy.
In a statement to STAT, Dr. Brian Kaspar said he “stands proudly behind the safety and efficacy of the drug.”
Access the full report here.
More articles on pharmacy:
FDA approves AbbVie’s $59K rheumatoid arthritis drug
Teva launches generic version of EpiPen for kids
American Regent boosted price of essential hospital product by 1,300%
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.